Skip to main content
PMC home page
Public Health Reports logoLink to Public Health Reports
. 1988 May-Jun;103(3):230–236.

The development of an AIDS vaccine: progress and promise.

A S Fauci 1, P J Fischinger 1
PMCID: PMC1478085  PMID: 3131812

Abstract

The development of a safe and effective vaccine against infection by the human immunodeficiency virus (HIV) is of paramount importance to the prevention of AIDS worldwide. Although a great deal has been learned about HIV in a few short years, the development of an AIDS vaccine has proved to be extremely difficult. The lack of an appropriate animal model for AIDS, the absence of a defined protective immune response in persons infected with HIV, the long latent period between initial infection and the development of symptoms, the existence of multiple strains of HIV, and the spread of HIV by way of cell-associated virus are issues that complicate the development of an effective AIDS vaccine. Researchers are employing a multifaceted approach to the creation of a potential AIDS vaccine. These approaches include the use of killed or attenuated virus, purified natural or synthetic subunits of the virus, infectious recombinant viruses, and anti-idiotypes. The first clinical trial of a subunit AIDS vaccine began in September 1987 at the National Institutes of Health (NIH). Through support of basic research on AIDS vaccine development and the establishment of a mechanism for clinical trials of candidate vaccines, NIH is pursuing multiple approaches toward the goal of a vaccine against AIDS.

Full text

PDF
236

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter H. J., Eichberg J. W., Masur H., Saxinger W. C., Gallo R., Macher A. M., Lane H. C., Fauci A. S. Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science. 1984 Nov 2;226(4674):549–552. doi: 10.1126/science.6093251. [DOI] [PubMed] [Google Scholar]
  2. Cease K. B., Margalit H., Cornette J. L., Putney S. D., Robey W. G., Ouyang C., Streicher H. Z., Fischinger P. J., Gallo R. C., DeLisi C. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci U S A. 1987 Jun;84(12):4249–4253. doi: 10.1073/pnas.84.12.4249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chakrabarti S., Robert-Guroff M., Wong-Staal F., Gallo R. C., Moss B. Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature. 1986 Apr 10;320(6062):535–537. doi: 10.1038/320535a0. [DOI] [PubMed] [Google Scholar]
  4. Fauci A. S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 1988 Feb 5;239(4840):617–622. doi: 10.1126/science.3277274. [DOI] [PubMed] [Google Scholar]
  5. Fischinger P. J., Gallo R. C., Bolognesi D. P. Toward a vaccine against AIDS: rationale and current progress. Mt Sinai J Med. 1986 Dec;53(8):639–647. [PubMed] [Google Scholar]
  6. Fultz P. N., McClure H. M., Swenson R. B., McGrath C. R., Brodie A., Getchell J. P., Jensen F. C., Anderson D. C., Broderson J. R., Francis D. P. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome. J Virol. 1986 Apr;58(1):116–124. doi: 10.1128/jvi.58.1.116-124.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fultz P. N., Srinivasan A., Greene C. R., Butler D., Swenson R. B., McClure H. M. Superinfection of a chimpanzee with a second strain of human immunodeficiency virus. J Virol. 1987 Dec;61(12):4026–4029. doi: 10.1128/jvi.61.12.4026-4029.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hahn B. H., Gonda M. A., Shaw G. M., Popovic M., Hoxie J. A., Gallo R. C., Wong-Staal F. Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc Natl Acad Sci U S A. 1985 Jul;82(14):4813–4817. doi: 10.1073/pnas.82.14.4813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hahn B. H., Shaw G. M., Taylor M. E., Redfield R. R., Markham P. D., Salahuddin S. Z., Wong-Staal F., Gallo R. C., Parks E. S., Parks W. P. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science. 1986 Jun 20;232(4757):1548–1553. doi: 10.1126/science.3012778. [DOI] [PubMed] [Google Scholar]
  10. Hunsmann G., Schneider J., Schulz A. Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes. Virology. 1981 Sep;113(2):602–612. doi: 10.1016/0042-6822(81)90188-4. [DOI] [PubMed] [Google Scholar]
  11. Kanki P. J., Alroy J., Essex M. Isolation of T-lymphotropic retrovirus related to HTLV-III/LAV from wild-caught African green monkeys. Science. 1985 Nov 22;230(4728):951–954. doi: 10.1126/science.2997923. [DOI] [PubMed] [Google Scholar]
  12. Koprowski H. Unconventional vaccines: immunization with anti-idiotype antibody against viral diseases. Cancer Res. 1985 Sep;45(9 Suppl):4689s–4690s. [PubMed] [Google Scholar]
  13. Lewis M. G., Mathes L. E., Olsen R. G. Protection against feline leukemia by vaccination with a subunit vaccine. Infect Immun. 1981 Dec;34(3):888–894. doi: 10.1128/iai.34.3.888-894.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mackett M., Smith G. L., Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A. 1982 Dec;79(23):7415–7419. doi: 10.1073/pnas.79.23.7415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McGuire T. C., Adams D. S., Johnson G. C., Klevjer-Anderson P., Barbee D. D., Gorham J. R. Acute arthritis in caprine arthritis-encephalitis virus challenge exposure of vaccinated or persistently infected goats. Am J Vet Res. 1986 Mar;47(3):537–540. [PubMed] [Google Scholar]
  16. Robey W. G., Safai B., Oroszlan S., Arthur L. O., Gonda M. A., Gallo R. C., Fischinger P. J. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science. 1985 May 3;228(4699):593–595. doi: 10.1126/science.2984774. [DOI] [PubMed] [Google Scholar]
  17. Sonigo P., Alizon M., Staskus K., Klatzmann D., Cole S., Danos O., Retzel E., Tiollais P., Haase A., Wain-Hobson S. Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus. Cell. 1985 Aug;42(1):369–382. doi: 10.1016/s0092-8674(85)80132-x. [DOI] [PubMed] [Google Scholar]
  18. Weiss R. A., Clapham P. R., Weber J. N., Dalgleish A. G., Lasky L. A., Berman P. W. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 1986 Dec 11;324(6097):572–575. doi: 10.1038/324572a0. [DOI] [PubMed] [Google Scholar]
  19. Zarling J. M., Morton W., Moran P. A., McClure J., Kosowski S. G., Hu S. L. T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. 1986 Sep 25-Oct 1Nature. 323(6086):344–346. doi: 10.1038/323344a0. [DOI] [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES